Pfizer Ltd. — Board/Management Information 2024

Jul 10, 2024

==> picture [100 x 42] intentionally omitted <==

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 10, 2024

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1[st] Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Intimation regarding change in Senior Management Personnel of the Company.

Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations’), the Company hereby wishes to inform that Ms. Shilpa Pradhan – Category Lead - Hospitals, Rare Disease and Inflammation & Immunology will be transitioning to a different role within Pfizer Group effective July 15, 2024 and shall accordingly cease to be a Senior Management Personnel effective the said date.

The Board of Directors of the Company, upon recommendation of the Nomination and Remuneration Committee has appointed Mr. Manikantan Seshadrinathan as Category Lead – Hospitals & Rare Disease effective July 29, 2024. Accordingly, Mr. Manikantan Seshadrinathan shall be a Senior Management Personnel effective the said date.

It is further informed that the Board of Directors of the Company, upon recommendation of the Nomination and Remuneration Committee, has appointed Mr. Saral Gupta as Director, Market Access effective August 1, 2024. Accordingly, Mr. Saral Gupta shall be a Senior Management Personnel effective the said date.

Additional details required to be disclosed pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and List/Comp/14/2018-19 dated June 20, 2018, are enclosed as Annexure A.

Request you to please take the above on record.

Thanking you,

Yours truly, For Pfizer Limited

PRAJEET Digitally signed by PRAJEET NAIR NAIR Date: 2024.07.10 16:23:15 +05'30' Prajeet Nair

Director – Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311 Email ID: contactus.india@pfizer.com Website: www.pfizerltd.co.in

Annexure A

Sr. no	Particulars	Particulars	Details	Details
1.	Name		Mr. Manikantan Seshadrinathan	Mr. Saral Gupta
2.	Reasons for change		Appointment of Mr. Manikantan Seshadrinathan as Category Lead – Hospitals & Rare Disease effective July 29, 2024. He will be a part of the Senior Management Personnel effective the said date.	Appointment of Mr. Saral Gupta as Director, Market Access effective August 1, 2024. He will be a part of the Senior Management Personnel effective the said date.
3.	Date of Appointment	~~and Term~~	July 29, 2024	August 1, 2024
4.	Affirmation as per List/Comp/14/2018-19 dated June 20, 2018		Not Applicable	Not Applicable
5.	Relationship inter-se Directors / Key Managerial Personnel / Senior Management Personnel		Mr. Manikantan Seshadrinathan is not related to any of the Directors / Key Managerial Personnel / Senior Management Personnel.	Mr. Saral Gupta is not related to any of the Directors / Key Managerial Personnel / Senior Management Personnel.
6.	Number of Shares held in the Company		Nil	Nil
7.	Brief Profile		• Mr. Manikantan Seshadrinathan brings over 18 years of rich experience predominantly with Stryker in both India and the US, where he has essayed diverse roles with increasing responsibilities across the R&D, Marketing and Business development functions. In his current role at Stryker India Private Limited, he serves as the Director for the Mako SmartRobotics vertical. • During his tenure at Boston Scientific, Mr. Seshadrinathan secured investments for three Asia Pacific, Middle East and Africa opportunities. He led the design and execution of disease state primary and secondary research alongside the R&D team across India and China. • Mr. Manikantan Seshadrinathan is a Bachelor in Engineering , Electronics & Communication from SSN College of Engineering and Masters in Biomedical Engineering from the University of Toledo.	• Mr. Saral Gupta has over 14 years of experience in pharmaceutical data analytics, business strategy consulting and commercial operations with a proven track record of building teams focused on excellence. • Mr. Saral Gupta joined Pfizer in 2017 as Lead - Sales Services - Strategy and held several positions of increasing responsibility. Before joining Pfizer, Mr. Gupta was a Senior Consultant at IQVIA, responsible for pharmaceutical business consulting, including commercial due diligence, growth strategy, Go-To-Market strategy, market intelligence, forecasting and primary market research, focused on Indian Pharmaceutical Markets. • Mr. Saral Gupta holds a Masters Degree in Technology in Process & Design Engineering and is a Bachelor of Technology in Chemical Engineering from IIT – Delhi.